PGEN

Company Overview — What Does PRECIGEN, INC. Do?

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland. PRECIGEN, INC. (PGEN) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Helen Sabzevari and employs approximately 190 people, headquartered in GERMANTOWN, Maryland. With a market capitalization of $1.4B, PGEN is one of the notable companies in the Healthcare sector.

PRECIGEN, INC. (PGEN) Stock Rating — Reduce (April 2026)

As of April 2026, PRECIGEN, INC. receives a Reduce rating with a composite score of 33.3/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.PGEN ranks #2,674 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, PRECIGEN, INC. ranks #358 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

PGEN Stock Price and 52-Week Range

PRECIGEN, INC. (PGEN) currently trades at $4.11. The stock lost $0.16 (3.7%) in the most recent trading session. Recent trading volume was 2.8M shares, reflecting moderate market activity.

Is PGEN Overvalued or Undervalued? — Valuation Analysis

PRECIGEN, INC. (PGEN) carries a value factor score of 24/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 69.73x, versus the sector average of 2.75x. The price-to-sales ratio is 37.64x, compared to 1.66x for the average Healthcare stock.

At current multiples, PRECIGEN, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

PRECIGEN, INC. Profitability — ROE, Margins, and Quality Score

PRECIGEN, INC. (PGEN) earns a quality factor score of 20/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -1200.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -161.5% versus the sector average of -33.1%.

On a margin basis, PRECIGEN, INC. reports gross margins of 59.0%, compared to 71.5% for the sector. The operating margin is -1141.1% (sector: -66.1%). Net profit margin stands at -2588.2%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

PGEN Debt, Balance Sheet, and Financial Health

PRECIGEN, INC. has a debt-to-equity ratio of 446.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 3.09x, indicating strong short-term liquidity. Total debt on the balance sheet is $93M. Cash and equivalents stand at $14M.

PGEN has a beta of 1.77, meaning it is more volatile than the broader market — a $10,000 investment in PGEN would be expected to move 76.9% more than the S&P 500 on any given day. The stability factor score for PRECIGEN, INC. is 20/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

PRECIGEN, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, PRECIGEN, INC. reported revenue of $10M and earnings per share (EPS) of $-1.37. Net income for the quarter was $-251M. Gross margin was 59.0%. Operating income came in at $-111M.

In FY 2025, PRECIGEN, INC. reported revenue of $10M and earnings per share (EPS) of $-1.37. Net income for the quarter was $-251M. Operating income came in at $-111M.

In Q3 2025, PRECIGEN, INC. reported revenue of N/A and earnings per share (EPS) of $-1.06. Net income for the quarter was $-146M.

In Q2 2025, PRECIGEN, INC. reported revenue of N/A and earnings per share (EPS) of $-0.09. Net income for the quarter was $-27M.

Over the past 8 quarters, PRECIGEN, INC. has reported varying levels of revenue. Investors analyzing PGEN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

PGEN Dividend Yield and Income Analysis

PRECIGEN, INC. (PGEN) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

PGEN Momentum and Technical Analysis Profile

PRECIGEN, INC. (PGEN) has a momentum factor score of 59/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 44/100 reflects moderate short selling activity.

PGEN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, PRECIGEN, INC. (PGEN) ranks #358 out of 838 stocks based on the Blank Capital composite score. This places PGEN in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing PGEN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full PGEN vs S&P 500 (SPY) comparison to assess how PRECIGEN, INC. stacks up against the broader market across all factor dimensions.

PGEN Next Earnings Date

No upcoming earnings date has been announced for PRECIGEN, INC. (PGEN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy PGEN? — Investment Thesis Summary

The quantitative profile for PRECIGEN, INC. suggests caution. The quality score of 20/100 flags below-average profitability. The value score of 24/100 indicates premium valuation. High volatility (stability score 20/100) increases portfolio risk.

In summary, PRECIGEN, INC. (PGEN) earns a Reduce rating with a composite score of 33.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on PGEN stock.

Related Resources for PGEN Investors

Explore more research and tools: PGEN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare PGEN head-to-head with peers: PGEN vs AZN, PGEN vs SLGL, PGEN vs VMD.